Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70086 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Timothy M Morgan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lachesis Biosciences Ltd., Breakwater, Victoria, Australia. Hauptthemen laut MEDLINE: Phenylcarbamates, Cholinesterase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Lachesis Biosciences and AusIndustry, Australian New Zealand Clinical Trials Registry.
Abstract (Originalsprache)
To compare the pharmacokinetics, bioavailability, tolerability, and safety of a novel 4 mg rivastigmine nasal spray to 3 mg rivastigmine oral capsule, a single‐dose, open‐label, randomized, crossover study was conducted in 16 fasted healthy young men (18 to 55 years). Mean (SD) rivastigmine C max was 8.39 (6.8) and 13.77 (10.7) ng/mL for oral and nasal, respectively. Rivastigmine AUC 0‐inf was 19.6 (14.9) and 40.6 (24.4) ng h/mL for oral and nasal, respectively. The ratio of LS means (nasal test / oral reference; 90% C.I.) for rivastigmine C max was 185.83% (134.22, 257.28) and for rivastigmine AUC 0‐inf was 257.35% (197.26, 335.73). Rivastigmine t max for nasal (0.7 h) was significantly lower than oral (1.2 h, P < .05), however, NAP226‐90 t max for nasal (1.9 h) and oral (1.8 h) were similar. NAP226‐90 C max was 3.93 (1.1) and 3.01 (0.8) ng/mL for oral and nasal, respectively. NAP226‐90 AUC 0‐inf was 22.9 (5.3) and 23.2 (5.1) ng h/mL for oral and nasal, respectively. Median NAP226‐90 to rivastigmine AUC 0‐inf ratio for nasal (0.55) was significantly lower than oral (1.38, P < .05) because nasal bypassed first‐pass metabolism. Both single‐dose treatments were safe and well tolerated. Nasal and throat irritation were mostly perceived as mild and transient following nasal administration. The 4 mg rivastigmine nasal spray had 1.5‐ and 2.0‐fold higher dose normalized rivastigmine C max and AUC 0‐inf , respectively, and 2.5‐fold lower NAP226‐90 to rivastigmine AUC 0‐inf ratio compared to 3 mg oral capsule. This nasal spray has good potential to improve the local and gastrointestinal tolerability of rivastigmine treatment in Alzheimer's and Parkinson's disease dementia patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lachesis Biosciences Ltd., Breakwater, Victoria, Australia.
- Nucleus Network, Department of General Medicine, Alfred Health, Melbourne, Victoria, Australia.
ORCID-Profile: Timothy M Morgan
Förderung
- Lachesis Biosciences and AusIndustry
- Australian New Zealand Clinical Trials Registry
Zitieren
APA
Morgan, T. M., & Snyder, B. (2026). Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70086
Vancouver
Morgan TM, Snyder B. Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70086
BibTeX
@article{Morgan2026,
author = {Morgan, Timothy M and Snyder, Benjamin},
title = {Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70086}
}
EUVIMED